Related Experiment Videos
[Comparison of digitoxin bioavailability from tablets and elixir during maintenance therapy (author's transl)]
Klinische Wochenschrift
|May 1, 1975
Summary
Digoxin bioavailability from tablets and solutions showed no significant differences in patients with heart failure. Steady-state analysis is preferred for assessing drug bioavailability during maintenance therapy.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Cardiovascular Medicine
Background:
- Digoxin is a crucial medication for managing congestive heart failure.
- Assessing the bioavailability of different digoxin formulations is essential for therapeutic efficacy.
- Maintenance therapy requires reliable drug absorption and consistent therapeutic levels.
Purpose of the Study:
- To compare the bioavailability of digoxin tablets versus solution during maintenance therapy.
- To evaluate the suitability of steady-state serum concentrations and urinary excretion as indices of bioavailability.
- To determine if steady-state conditions better reflect typical digoxin treatment.
Main Methods:
- A crossover study design was employed.
- Patients with compensated congestive heart failure received either digoxin tablets or solution for at least 7 days.
- Plasma levels and urine concentrations of digitoxin were analyzed.
Main Results:
- No significant differences in bioavailability were observed between digoxin tablets and solution.
- While more cumbersome, steady-state analyses offer a more pharmacokinetically sound assessment of bioavailability.
- Steady-state conditions closely mimic standard clinical digitalis therapy.
Conclusions:
- Digoxin tablets and solution exhibit comparable bioavailability in patients with compensated congestive heart failure.
- Steady-state pharmacokinetic analysis provides a more robust evaluation of digoxin bioavailability during maintenance therapy.
- Understanding bioavailability differences is critical for optimizing patient treatment regimens.